FDA grants Roche’s pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
8 February 2012 | By Roche
The U.S. FDA has accepted the company’s Biologics License Application for pertuzumab...
List view / Grid view
8 February 2012 | By Roche
The U.S. FDA has accepted the company’s Biologics License Application for pertuzumab...
30 January 2012 | By
The first medicine for adults with advanced basal cell carcinoma...
27 January 2012 | By Roche
Roche has commenced a cash tender offer to acquire all outstanding shares of Illumina, Inc....
26 January 2012 | By Roche
Roche has responded to an announcement from Illumina, Inc...
25 January 2012 | By Roche
Roche announced that it is proposing to acquire all outstanding shares of Illumina, Inc...
23 January 2012 | By Roche
Establishment of a program to improve basic cancer care in Ethiopia...
19 December 2011 | By Roche
For the treatment of people with BRAF mutation-positive metastatic melanoma...
15 December 2011 | By Merck
New clinical trial will evaluate an investigational therapeutic regimen with VICTRELIS™ (boceprevir)...
15 December 2011 | By Roche
Roche announced that Sophie Kornowski-Bonnet has been appointed Head of Roche Partnering...
8 December 2011 | By Roche
6.1 month improvement in median progression free survival, from 12.4 to 18.5 months...
1 December 2011 | By Roche
Roche have announced that the cobas EGFR Mutation Test is now CE marked...
30 November 2011 | By Roche
Results from studies to be presented at SABCS...
18 November 2011 | By Roche
FDA Commissioner revokes approval of Avastin for treatment of mBC in the US...
9 November 2011 | By Roche
The vismodegib application has been granted priority review...
20 October 2011 | By Roche
Phase III trials underway to investigate ocrelizumab in two forms of MS...